| Cardiovascular and renal outcomes with empagliflozin in heart failure M Packer, SD Anker, J Butler, G Filippatos, SJ Pocock, P Carson, ... New England Journal of Medicine 383 (15), 1413-1424, 2020 | 4711 | 2020 |
| Empagliflozin in heart failure with a preserved ejection fraction SD Anker, J Butler, G Filippatos, JP Ferreira, E Bocchi, M Böhm, ... New England Journal of Medicine 385 (16), 1451-1461, 2021 | 3853 | 2021 |
| Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... New England Journal of Medicine 381 (17), 1609-1620, 2019 | 2296 | 2019 |
| Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes GL Bakris, R Agarwal, SD Anker, B Pitt, LM Ruilope, P Rossing, P Kolkhof, ... New England journal of medicine 383 (23), 2219-2229, 2020 | 2066 | 2020 |
| Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ... New England Journal of Medicine 381 (9), 841-851, 2019 | 1691 | 2019 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1551 | 2018 |
| Cardiovascular events with finerenone in kidney disease and type 2 diabetes B Pitt, G Filippatos, R Agarwal, SD Anker, GL Bakris, P Rossing, A Joseph, ... New England Journal of Medicine 385 (24), 2252-2263, 2021 | 1193 | 2021 |
| Practical recommendations for the management of diabetes in patients with COVID-19 SR Bornstein, F Rubino, K Khunti, G Mingrone, D Hopkins, AL Birkenfeld, ... The lancet Diabetes & endocrinology 8 (6), 546-550, 2020 | 1117 | 2020 |
| Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes AL Birkenfeld, GI Shulman Hepatology 59 (2), 713-723, 2014 | 895 | 2014 |
| Safety and efficacy of bempedoic acid to reduce LDL cholesterol KK Ray, HE Bays, AL Catapano, ND Lalwani, LAT Bloedon, LR Sterling, ... New England Journal of Medicine 380 (11), 1022-1032, 2019 | 788 | 2019 |
| Obesity and impaired metabolic health in patients with COVID-19 N Stefan, AL Birkenfeld, MB Schulze, DS Ludwig Nature Reviews Endocrinology 16 (7), 341-342, 2020 | 751 | 2020 |
| Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled … PM O'Neil, AL Birkenfeld, B McGowan, O Mosenzon, SD Pedersen, ... The Lancet 392 (10148), 637-649, 2018 | 745 | 2018 |
| Bempedoic acid and cardiovascular outcomes in statin-intolerant patients SE Nissen, AM Lincoff, D Brennan, KK Ray, D Mason, JJP Kastelein, ... New England Journal of Medicine 388 (15), 1353-1364, 2023 | 611 | 2023 |
| Global pandemics interconnected—obesity, impaired metabolic health and COVID-19 N Stefan, AL Birkenfeld, MB Schulze Nature Reviews Endocrinology 17 (3), 135-149, 2021 | 499 | 2021 |
| Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 … J Rosenstock, D Allison, AL Birkenfeld, TM Blicher, S Deenadayalan, ... Jama 321 (15), 1466-1480, 2019 | 392 | 2019 |
| Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects S Haufe, S Engeli, P Kast, J Böhnke, W Utz, V Haas, M Hermsdorf, ... Hepatology 53 (5), 1504-1514, 2011 | 379 | 2011 |
| Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance HY Lee, CS Choi, AL Birkenfeld, TC Alves, FR Jornayvaz, MJ Jurczak, ... Cell metabolism 12 (6), 668-674, 2010 | 362 | 2010 |
| Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes R Wagner, M Heni, AG Tabak, J Machann, F Schick, E Randrianarisoa, ... Nature medicine 27 (1), 49-57, 2021 | 313 | 2021 |
| Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial S Kahl, S Gancheva, K Straßburger, C Herder, J Machann, H Katsuyama, ... Diabetes care 43 (2), 298-305, 2020 | 310 | 2020 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial C Mathieu, P Dandona, P Gillard, P Senior, C Hasslacher, E Araki, M Lind, ... Diabetes care 41 (9), 1938-1946, 2018 | 265 | 2018 |
